To accelerate clinical diagnostic testing for COVID-19 in the 61 United States, the FDA on February 28th, 2020 permitted individual clinically licensed 62 laboratories to report the results of in-house developed SARS-CoV-2 diagnostic assays 63 while awaiting results of an EUA submission for approval 7 .